• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.
By BRET JENSEN
Jan 27, 2018 | 02:00 PM EST
Stocks quotes in this article: GILD, KITE, JUNO, BLUE, FOLD

Last year was a punk one for deals across the biotech and pharma industries. According to PWC, global deal volume dropped 23% across the Life Sciences sector, which encompasses both of these industries. Companies largely sat on their hands waiting to see what, if any, changes were coming for the tax structure in the United States.

Now that clarity has been provided from the tax reform bill signed into law a bit over a month ago, mergers-and-acquisitions activity already seems to be picking up steam.

On Monday we saw two significant deals totaling over $20 billion announced. Both contained substantial buyout premiums. Increased deal volume in 2018 across biotech and pharma is a likely theme I have been discussing on these pages for several months now.

So, what are some of the potential targets of this new wave of acquisitions? Let's engage in some speculation.

In late August, Gilead Sciences (GILD) paid $12 billion to acquire CAR-T concern Kite Pharma (KITE) , which had a key late-stage compound (now approved). Early this week, Celgene acquired another CAR-T firm Juno Therapeutics (JUNO) for $9 billion, paying a roughly 90% premium to what the stock was trading before news of the buyout talks came to light. Juno has a late-stage compound that is on target to be approved in 2019 for a type of lymphoma. Celgene had a collaboration deal with and 10% equity stake in Juno prior to the purchase

If the trend holds, one has to think that CAR-T concern bluebird Bio (BLUE) might be next in the cross hairs. Bluebird's main asset is a late-stage biologic targeting relapsed multiple myeloma. As it happens, Celgene also has a collaboration with this CAR-T concern and would be the most logical suitor.

Outside of oncology, I think the rare disease area is a good target for M&A in the year ahead. The new focus at the FDA to streamline the drug-approval process, especially when no or few treatments exist, bodes well for this sub-sector of the biotech industry. In addition, these purchases can be quickly accretive as they address areas where most of the afflicted individuals are already known and can be served by a small salesforce.

Amicus Therapeutics (FOLD) would be a logical pick up for a larger concern. It has one approved product, "Galafold," in Europe that targets Fabry Disease and is seeing a rapid rollout. The compound should be greenlighted in the U.S. soon.

In addition, Amicus has a late-stage compound targeting Pompe Disease. The company could push for accelerated approval of this drug based on mid-stage trial data but more likely will go with a Phase III trial data for which would be out in 2020. There is an existing drug for this rare disease that is climbing toward $1 billion in annual sales. Amicus's compound is looking like it is seeing much improved outcomes in studies so far.

With a market cap of under $2.7 billion, Amicus could see some interest from suitors in 2018.

This commentary originally appeared on Real Money Pro on Jan. 26. Click here to learn about this dynamic market information service for active traders.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long CELG, GILD and FOLD.

TAGS: Investing | U.S. Equity | Healthcare | How-to | Mergers and Acquisitions | Stocks

More from Healthcare

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

CVS Stock Needs to Refill Its Prescription

Bruce Kamich
Mar 29, 2022 12:01 PM EDT

Charts are looking 'toppy' right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:14 PM EDT PAUL PRICE

    A New, Very Scary Movie

  • 08:51 AM EDT PAUL PRICE

    Advice From the Future...

  • 12:20 PM EDT PAUL PRICE

    A Blast From the Past Regarding Bitcoin

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login